| abstract |
REFERRED TO QUINOLINE DERIVATIVES AS ANTAGONISTS OF NEUROPEPTIDE AND (NPY), FROM FORMULA I WHERE R1 AND R2 ARE HYDROGEN, ALKYL, CYCLOALKYL, CYCLOALKYLALKYL, ALKYLCARBONYL, CYCLOALKYL CARBONYL, ARTHRALKYL CARBONYL; OR TOGETHER WITH THE N ATOM THEY ARE A 5-10 LINK HETEROCICLIC RING THAT MAY HAVE A SECOND HETEROATOM LIKE N OR O, AND THIS RING MAY HAVE ONE OR SEVERAL SUBSTITUTES LIKE ALKYL OR ALCOXY; R3 IS HYDROGEN, ALKYL, AMINE OR HALOGEN; R4 IS HYDROGEN, HALOGEN, HETEROCYCLYL, AMINE OR ALKYL; A IS A SATURATED HETEROCYCLIC RING OF 5 TO 7 LINKS THAT CONTAINS AN N THAT IS JOINED TO THE QUINOLINE RING AND MAY HAVE A SECOND HETEROATOME AS O, ARE, AND THIS EVENTUALLY SUBSTITUTE THREE TIMES BY ALKYL, HYDROXY, ALCOX ACETHYLAMINE, CYANE, HYDROXYALKYL, ALCOXYALKYL, AMONG OTHERS. PREFERRED COMPOUNDS ARE: (2-METHYL-4-PYRROLIDIN-1-IL-QUINOLIN-7-IL) -CYCLOPROPANOCARBOXYL ACID (2-DIMEOXYL -METHYL-4-PYRROLIDIN-1-IL-QUINOLIN-7-IL) -PROPIONAMIDE, 4- (2-METHYL-4-PYRROLIDIN-1-IL-QUINOLIN-7-ILAMINO) -BENZONITRILE, AMONG OTHERS. IT ALSO REFERS TO A PROCESS FOR OBTAINING THE COMPOUND AND A PHARMACEUTICAL COMPOSITION. THE COMPOUND MAY BE USED FOR THE TREATMENT AND PROPHYLAXIS OF ARTHRITIS, CARDIOVASCULAR DISEASES, DIABETES, KIDNEY FAILURE AND OBJECTIVES, TRANSTORIAL |